ArticleFrontiers in immunology2026
Cytokine imbalance and immune network endotypes underlying heterogeneous response to omalizumab in chronic spontaneous urticaria.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic spontaneous urticaria (CSU) exhibits marked immunologic heterogeneity, and a substantial proportion of patients show delayed or absent responses to anti-IgE therapy. While cytokines are implicated in CSU pathophysiology, their integrated network architecture in relation to treatment response remains poorly understood. Methods: We analyzed serum cytokine profiles in 65 antihistamine-refractory CSU patients who received omalizumab for ≥ 6 months. Fifteen cytokines were quantified at baseline and month 6 using a multiplex bead-based assay. Treatment responses were categorized as early and well-controlled (EW), late or partly controlled (LP), or no-response (NR) based on UAS7 and UCT criteria. Cytokine compositional balance, network topology, multinomial regression, and structural equation modeling were applied to delineate immune endotypes associated with treatment response. Results: Of 65 patients, 33 (50.8%) were EW, 16 (24.6%) were LP, and 16 (24.6%) were NR. Among baseline cytokines, interleukin (IL)-13 was the only analyte differing significantly in absolute concentration, being higher in LP and NR than in EW patients. Compositional analyses revealed an IL-13-dominant imbalance strongly enriched in LP and NR. Cytokine-network analysis demonstrated cohesive interactions in EW, partial disruption in LP, and fragmented innate-Th17/Th1 connectivity in NR. Multinomial regression and structural path analyses identified IL-13 as a central node linking multiple inflammatory pathways associated with inadequate response. Longitudinally, meaningful cytokine modulation was observed only in EW, whereas LP and NR exhibited minimal or no changes despite treatment. Conclusion: Baseline cytokine imbalances and network architecture are closely associated with heterogeneity in omalizumab response. An IL-13-dominant, biologically rigid cytokine profile, together with persistent innate-Th17 activity in certain patients, may define CSU endotypes less amenable to anti-IgE therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.